Venture:
Vive (formerly QuikReversal)
Founders:
Asher Varon '18SGS '18JTS
Industry:
Health care, medtech, and pharmaceuticals
Venture Type:
For-profit
What is the social or environmental issue being addressed?
Over 107,000 people die from drug overdose, annually, in the United States alone. The antidote naloxone is used in an attempt to curb fatal outcomes. However, naloxone requires both a bystander’s recognition of overdose and ability to administer it. If left untreated, overdose conditions can cause fatality in four minutes. Therefore, there is a need to create a solution that allows for automatic overdose detection and naloxone delivery without requiring a bystander. Vive's mission is to provide a lifeline, guiding individuals with opioid use disorder from survival to proven avenues of sustainable treatment and recovery, ultimately saving 36 million lives worldwide.
Innovation:
Serving as a safety-net for those with opioid use disorder, Vive is developing a disposable, non-electronic, wearable that can automatically detect lethal opioid overdose and deliver the antidote, naloxone.
Read More:
- Three Columbia Healthcare Innovation Founders Earn $50,000 in Award Funds at the Annual Columbia-CareOne Healthcare Innovation Invitational
CareOne
May 4, 2023 - Tackling the Opioid Crisis
NYU News
February 25, 2020